Schiff Nutrition rides private label growth
This article was originally published in The Tan Sheet
Executive Summary
The nutritional company's net sales rose 7.9 percent to 49.9 million on the strength of private label business in the fiscal third quarter (ended Feb. 28), though branded business hampered net sales in the period, the Salt Lake City-based firm reports March 17. Though Schiff's Move Free brand sales fell in the mid-single digits, MegaRed Krill Oil performed well, due in part to increased marketing, Schiff President and CEO Bruce Wood says. However, the National Advertising Division told Schiff to modify misleading MegaRed ad claims (1"The Tan Sheet" March 9, 2009, p. 10). Net earnings for the quarter were $3.6 million, compared to $4 million in the same period last year, negatively impacted by a compensation charge related to a special dividend. Schiff will continue supporting Move Free and MegaRed products and will "continue our efforts to explore other branded and private label organic growth opportunities as well as potential acquisition opportunities," Wood says
You may also be interested in...
Congress Says GAO Report Supports Increasing Supplement Oversight
Key congressional leaders want to give FDA tighter control over dietary supplements, saying a Government Accountability Office report critical of the agency's enforcement supports granting additional authority
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.